Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Blood pressure, stroke, and coronary heart disease
19903.4k citationsStephen MacMahon et al.profile →
Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
Countries citing papers authored by Stephen MacMahon
Since
Specialization
Citations
This map shows the geographic impact of Stephen MacMahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen MacMahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen MacMahon more than expected).
Fields of papers citing papers by Stephen MacMahon
This network shows the impact of papers produced by Stephen MacMahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen MacMahon. The network helps show where Stephen MacMahon may publish in the future.
Co-authorship network of co-authors of Stephen MacMahon
This figure shows the co-authorship network connecting the top 25 collaborators of Stephen MacMahon.
A scholar is included among the top collaborators of Stephen MacMahon based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Stephen MacMahon. Stephen MacMahon is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Peiris, David, Stephen MacMahon, Kishor Mogulluru, et al.. (2018). Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology 11 Medica. BMC Public Health. 18.
Lv, Jicheng, Bruce Neal, Mark Woodward, et al.. (2012). Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine. 9(8). e1001293–e1001293.560 indexed citations breakdown →
8.
Hata, Junya, Hisatomi Arima, Peter M. Rothwell, et al.. (2012). Visit-to-visit Variability of Systolic Blood Pressure Predicts Macrovascular and Microvascular Events in Patients with Type 2 Diabetes: the ADVANCE Trial. International Journal of Stroke. 7. 13–13.1 indexed citations
9.
Ninomiya, Toshiharu, Sophia Zoungas, Bastiaan E. de Galan, et al.. (2009). THE FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE HAS A GREATER EFFECT ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND ALBUMINURIA. Journal of Hypertension. 27.1 indexed citations
10.
Chalmers, John, Vlado Perkovic, T. Ninomiya, et al.. (2008). Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: Results of the ADVANCE trial. Journal of Hypertension. 26.1 indexed citations
11.
Patel, Anushka, Hideki Horibe, Zhendong Wu, et al.. (2007). Cholestrol, coronary heart disease, and stroke in the Asia Pacific region (2007).2 indexed citations
12.
Dufouil, Carole, John Chalmers, M.G. Bousser, et al.. (2005). Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke. The PROGRESS MRI Substudy. Circulation. 112.4 indexed citations
13.
Chalmers, John, Bruce Neal, & Stephen MacMahon. (2000). PROGRESS (Perindopril Protection Against Recurrent Stroke Study): Regional characteristics of the study population at baseline. Journal of Hypertension. 18(11). 1647–1655.28 indexed citations
14.
White, HD, R. John Simes, Neil E. Anderson, et al.. (2000). Pravastatin therapy and the risk of stroke: results from the LIPID study. New England Journal of Medicine. 343.2 indexed citations
15.
Collins, Robert T., et al.. (1999). The pulmonary embolism prevention (PEP) trial: Effects of low-dose aspirin on major vascular events in patients with hip fracture. Thrombosis and Haemostasis. 193–193.1 indexed citations
16.
Aylward, Philip E., David Colquhoun, Paul Glasziou, et al.. (1995). Lowering Cholesterol Levels in Patients with Coronary Heart-Disease - the 4s Trial Showed That Lowering High Cholesterol Levels Improves Survival in Patients with Coronary Heart-Disease - Do the Benefits Extend to Those with Average Cholesterol Levels. The Medical Journal of Australia. 162(9). 455–456.2 indexed citations
Zanchetti, Alberto, John Chalmers, Kikuo Arakawa, et al.. (1993). 1993 Guidelines for the management of mild hypertension: MEMORANDUM from a World Health Organization/International Society of Hypertension meeting. Journal of Hypertension. 11(9). 905–918.203 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.